Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 8/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 8/20 | 0.32 |
| ▸ | PPARG | P37231 | 7/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | GJB2 | P29033 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15888756 | 0.83 | SLC5A2 (0.36) | SLC5A2MEN1KMT2ASSTR1SSTR2 | |
| SCHEMBL222748 | 0.83 | SLC5A2 (0.36) | SLC5A2MEN1KMT2ASSTR1SSTR2 | |
| SCHEMBL12070133 | 0.83 | SLC5A2 (0.33) | SLC5A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL14841444 | 0.83 | PTPN1 (0.41) | — | |
| SCHEMBL2600477 | 0.81 | SLC5A2 (0.41) | SLC5A2 | |
| SCHEMBL14236379 | 0.79 | SLC5A2 (0.45) | SLC5A2 | |
| SCHEMBL2600479 | 0.79 | SLC5A2 (0.45) | SLC5A2 | |
| SCHEMBL14235767 | 0.79 | SLC5A2 (0.45) | SLC5A2 | |
| SCHEMBL2600503 | 0.78 | SLC5A2 (0.39) | SLC5A2 | |
| SCHEMBL12650128 | 0.78 | SLC5A2 (0.35) | SLC5A2SSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | GREEN CROSS CORPORATION (KR) | 2013-04-11 | — | — | US | disclosed |
| WO-2011159067-A2 | THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | SLC5A2, SLC5A1, SLC10A2 | SLC5A2 1/4885MEN1 3593/4885KMT2A 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.